Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peyman Hadji

Showing results (111-120 of 171) with videos related to

Pageof 18
Sort By:
Critical Reviews in Oncology/Hematology|March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease settingRobert Coleman, Luis Costa, Fred Saad, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 30, 2008
Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official PositionsDidier B Hans, John A Shepherd, Elliott N Schwartz, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)Richard Eastell, Thomas Nickelsen, Fernando Marin, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 18, 2016
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implicationsStefan Stefanovic, Markus Wallwiener, Uros Karic, et al.
Breast Cancer Research : BCR|February 18, 2014
Dickkopf-1 is regulated by the mevalonate pathway in breast cancerTilman D Rachner, Andy Göbel, Stefanie Thiele, et al.
Calcified Tissue International|March 27, 2025
Bone Effects of Anti-Cancer Treatments in 2024Marie Teissonnière, Mathieu Point, Emmanuel Biver, et al.
Onkologie|April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health systemMichael P Lux, Achim Wöckel, Agnes Benedict, et al.
Cancer Treatment Reviews|May 19, 2010
Metastasis and bone loss: advancing treatment and preventionRobert E Coleman, Allan Lipton, G David Roodman, et al.
International Journal of Cancer|July 12, 2018
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trialHans Tesch, Oliver Stoetzer, Thomas Decker, et al.
Pageof 18

Showing results (111-120 of 171) with videos related to

Sort By:
Pageof 18
Critical Reviews in Oncology/Hematology|March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease settingRobert Coleman, Luis Costa, Fred Saad, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|April 30, 2008
Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official PositionsDidier B Hans, John A Shepherd, Elliott N Schwartz, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)Richard Eastell, Thomas Nickelsen, Fernando Marin, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 18, 2016
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implicationsStefan Stefanovic, Markus Wallwiener, Uros Karic, et al.
Breast Cancer Research : BCR|February 18, 2014
Dickkopf-1 is regulated by the mevalonate pathway in breast cancerTilman D Rachner, Andy Göbel, Stefanie Thiele, et al.
Calcified Tissue International|March 27, 2025
Bone Effects of Anti-Cancer Treatments in 2024Marie Teissonnière, Mathieu Point, Emmanuel Biver, et al.
Onkologie|April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health systemMichael P Lux, Achim Wöckel, Agnes Benedict, et al.
Cancer Treatment Reviews|May 19, 2010
Metastasis and bone loss: advancing treatment and preventionRobert E Coleman, Allan Lipton, G David Roodman, et al.
International Journal of Cancer|July 12, 2018
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trialHans Tesch, Oliver Stoetzer, Thomas Decker, et al.
Pageof 18